三阴乳腺癌细胞中Atg13基因的过表达与化疗耐药的研究

doi:10.16689/j.cnki.cn11-9349/r.2019.03.008

摘要
图/表
参考文献
相关文章 (1)

全文: PDF (3142 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨自噬相关基因13（Atg13）与三阴性乳腺癌的化疗耐药之间的关系。方法间歇刺激法构建对阿霉素耐受的MDA-MB-231 TNBC细胞株（命名为MDA-MB-231/Dox），并采用药物敏感实验和细胞凋亡实验（TUNEL染色）对耐药细胞株MDA-MB-231/Dox的耐药表型进行鉴定；蛋白免疫印迹实验检测敏感细胞MDA-MB-231和耐药细胞MDA-MB-231/Dox中的自噬相关蛋白LC3A、LC3B的表达情况，免疫荧光法测定细胞内的LC3B荧光斑点数；脂质体转染重组干扰质粒sh-Atg13至耐药细胞MDA-MB-231/Dox中，并经嘌呤霉素筛选得到稳转细胞（命名为MDA-MB-231/Dox + sh-Atg13），蛋白免疫印迹实验检测稳转细胞MDA-MB-231/Dox+sh-Atg13及空载体对照细胞MDA-MB-231/Dox+control plasmid中的Atg13蛋白表达水平，同时检测细胞内的自噬水平（自噬相关蛋白LC3A、LC3B的表达量及LC3B荧光斑点数）及各组细胞对Dox的药物敏感性。结果成功构建对Dox耐药的TNBC细胞株MDA-MB-231/Dox，并且发现耐药细胞中的基础自噬水平显著高于亲本细胞MDA-MB-231（P<0.05）。重组干扰质粒sh-Atg13抑制Atg13基因表达后，使得耐药细胞MDA-MB-231/Dox中的自噬体标志分子LC3B蛋白表达量显著降低（P<0.05），且耐药细胞对Dox的药物敏感性增加（IC50值显著降低，P<0.05）。结论在TNBC细胞MDA-MB-231中，Atg13参与了细胞对Dox获得性耐药的产生。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	1 刘永波
	2
	3邓丽
	1郭怡辉
	1李艳萍

关键词 ：三阴性乳腺癌, 自噬, Atg13, 化疗耐药

Abstract：Objective To explore the impact of gene 13(Atg13) on promoting chemotherapy resistance in triple-negative breast cancer (TNBC) cells. Methods We developed a doxorubicin-resistant MDA-MB-231/Dox cell lines using intermittent application of doxorubicin (Dox). MDA-MB-231/Dox was determined by the drug-sensitive assay and the apoptosis assay (TUNEL staining).The expression of LC3A and LC3B in TNBC cells (MDA-MB-231 and MDA-MB-231/Dox) was detected by Western Blot (WB). The number of LC3B fluorescence spots in the cells was quantified by immunofluorescence. Recombinant plasmid sh-Atg13 was transfected into MDA-MB-231/Dox by liposome， then stable cells (referred to as MDA-MB-231/Dox+sh-Atg13) were obtained by puromycin screening (PM). The Atg13 expression level in MDA-MB-231/Dox+sh-Atg13 and empty plasmid MDA-MB-231/Dox+control plasmid by WB. Changes in autophagy activity were determined by the level of LC3A， LC3B expression and the number of LC3B fluorescent spots. Drug sensitivity of each cell line to Dox was also examined. Results Dox-resistant TNBC cell line MDA-MB-231/Dox were successfully established in vitro. The results showed that the level of basal autophagy in drug-resistant cells was significantly higher than that in sensitive cells MDA-MB-231(P<0.05). After inhibiting the expression of Atg13 gene by recombinant interference plasmid sh-Atg13， the protein expression of autophagy marker LC3B in drug-resistant cells MDA-MB-231/Dox was significantly decreased (P<0.05)， the drug sensitivity of MDA-MB-231/Dox cells to Dox was increased (IC50 value was significant， P<0.05). Conclusion In TNBC cell MDA-MB-231， Atg13 increased chemotherapy resistance by inducing autophagy were determined.

Key words： Triple-negative breast cancer Autophagy Atg13 Chemotherapy resistance

基金资助:江西省科技厅青年科学基金（20161BAB215187）

通讯作者: 李艳萍，电子邮箱：lyp05188@163.com

引用本文:

1 刘永波，2，3邓丽，1郭怡辉，1李艳萍. 三阴乳腺癌细胞中Atg13基因的过表达与化疗耐药的研究[J]. 肿瘤代谢与营养电子杂志, 2019, 6(3): 310-315.
1LIU Yong-bo，2，3DENG Li， 1GUO Yi-hui，1LI Yan-ping. Atg13 gene overexpression induces chemotherapy resistance in triple-negative breast cancer cells. Electron J Metab Nutr Cancer, 2019, 6(3): 310-315.

1.Woolston C. Breast cancer:4 big questions. Nature. 2015;527(7578):S120.
2.Jiao Q， Wu A， Shao G， et al.The latest progress in research on triple negative breast cancer (TNBC): risk factors， possible therapeutic targets and prognostic markers.J Thorac Dis. 2014;6(9):1329-1335.
3.McCann KE， Hurvitz SA， McAndrew N. Advances in targeted therapies for triple-negative breast cancer.Drugs. 2019;79(11):1217-1230.
4.Pusztai L， Foldi J， Dhawan A，et al. Changing frameworks in treatment sequencing of triple-negative and HER2-positive， early-stage breast cancers.Lancet Oncol. 2019;20(7):e390-e396.
5.Planes-Laine G， Rochigneux P， Bertucci F，et al. PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging. A literature review.Cancers (Basel). 2019;11(7):E1033.
6.Novikov O，Wang Z，Stanford EA，et al.An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER-/PR-/Her2-human breast cancer cells. Mol Pharmacol. 2016;90(5):674-688.
7.Aydinlik S，Erkisa M，Cevatemre B，et al.Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line. Biochim Biophys Acta Gen Subj. 2017;1861(2):49-57.
8.Woo SM， Kim AJ， Choi YK， et al. Synergistic effect of SH003 and doxorubicin in triple-negative breast cancer.Phytother Res. 2016;30(11):1817-1823.
9.Angelini A， Conti P， Ciofani G， et al. Modulation of multidrug resistance P-glycoprotein activity by antiemetic compounds in human doxorubicin-resistant sarcoma cells (MES-SA/Dx-5): implications on cancer therapy. J Biol Regul Homeost Agents. 2013;27(4):1029-1037.
10.Pan YZ， Wang X， Bai H， et al. Autophagy in drug resistance of the multiple myeloma cell line RPMI8226 to doxorubicin.Genet Mol Res. 2015;14(2):5621-5629.
11.Kochel TJ， Reader JC， Ma X， et al. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2(PGE2) and contributes to metastasis in basal/triple negative breast cancer.Oncotarget. 2017;8(4):6540-6554.
12.Zhang L， Shamaladevi N， Jayaprakasha GK， et al. Polyphenol-rich extract of Pimenta dioica berries (Allspice) kills breast cancer cells by autophagy and delays growth of triple negative breast cancer in athymic mice.Oncotarget. 2015;6(18):16379-16395.
13.Brand JS， Hedayati E， Humphreys K， et al.Chemotherapy， genetic susceptibility， and risk of venous thromboembolism in breast cancer patients.Clin Cancer Res. 2016;22(21):5249-5255.
14.Xu SW， Law BY， Mok SW， et al. Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. Int J Oncol. 2016;49(4):1576-1588.
15.Wang W， Kang H， Zhao Y， et al. Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J Clin Endocrinol Metab. 2017;102(2):634-643.
16.Zhong JT， Yu J， Wang HJ， et al. Effects of endoplasmic reticulum stress on the autophagy， apoptosis， and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway. Tumour Biol. 2017;39(5):1010428317697562.
17.Cheong JW， Kim Y， Eom JI， et al. Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance. Mol Med Rep. 2016;13(4):3433-3440.
18.Guo B， Tam A， Santi SA， et al. Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells. BMC Cancer. 2016;16(1):762.
19.Ladoire S， Enot D， Senovilla L， et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy. 2016;12(5):864-875.
20.Zhao H， Yang M， Zhao J， et al. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer. Med Oncol. 2013;30(1):475.